3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
310
Squamous Cell Carcinoma of Head and Neck
163
Head and Neck Neoplasms
145
Carcinoma, Non-Small-Cell Lung
97
Colonic Neoplasms
89
Rectal Neoplasms
81
Neoplasm Metastasis
70
Neoplasms
59
Pancreatic Neoplasms
40
Carcinoma, Squamous Cell
38
Lung Neoplasms
35
Esophageal Neoplasms
25
Breast Neoplasms
22
Stomach Neoplasms
20
Recurrence
20
Laryngeal Neoplasms
17
Carcinoma
17
Tongue Neoplasms
16
Mouth Neoplasms
16
Esophageal Squamous Cell Carcinoma
14
Oropharyngeal Neoplasms
13
Salivary Gland Neoplasms
12
Adenocarcinoma Of Esophagus
12
Hypopharyngeal Neoplasms
11
Laryngeal Diseases
10
Adenocarcinoma of Lung
10
Uterine Cervical Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Ovarian Neoplasms
9
Nasopharyngeal Carcinoma
9
Interventions
osimertinib
2
sotorasib
1
pembrolizumab
1
nazartinib
1
cobimetinib
1
Waiting Lists
1
Lovastatin
1
Lamotrigine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Noonan Syndrome
×
Cetuximab
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled